年恶性淋巴瘤疗效评价标准.ppt

“REVISED RESPONSE CRITERIA FOR MALIGNANT LYMPHOMA” J Clin Oncol 25:579-586. ? 2007 by American Society of Clinical Oncology Cheson et al, J Clin Oncol 17:1244, 1999 In 1999, an International Working Group (IWG) of clinicians, radiologists, and pathologists with expertise in the evaluation and management of patients with Lymphoma published guidelines for response assessment and outcomes measurement. Response Criteria for Lymphoma Definitions of End Points for Clinical Trials Standardized response criteria provide uniform end points for clinical trials: Allowing for comparisons among studies Facilitating the identification of more effective therapies The widely used IWG criteria for response assessment of lymphoma are based predominantly on CT.It became clear that the International Working Group criteria warranted revision, because of identified limitations and the increased use of : [18F] fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), flow cytometry, molecular biology “REVISED RESPONSE CRITERIA FOR MALIGNANT LYMPHOMA” J Clin Oncol 25:579-586. ? 2007 by American Society of Clinical Oncology The Competence Network Malignant Lymphoma convened an International Harmonization Project at which 5 subcommittees were formed: Response Criteria End Points for Clinical Trials Imaging Clinical Features Pathology/Biology Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25:571-578. ? 2007 by American Society of Clinical Oncology PET- PET/CT PET using [18F]fluorodeoxyglucose (FDG, a radioactive derivative of glucose, is an advanced imaging tool, based on the increased glucose consumption of cancer cells), has emerged as a powerful functional imaging tool for staging, restaging, and response assessment of lymphomas. The advantage of PET over conventional imaging techniques, such as TC or RMN, is its ability t